Cardiol Therapeutics (CRDL) Cash from Operations (2020 - 2026)

Cardiol Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 5481899.32 for Q1 2026.

• Quarterly Cash from Operations fell 9.96% year-over-year to 5481899.32 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17545050.36 (up 3.47% YoY) and the FY2025 annual result came in at 17105842.3, up 4.65% from the prior year.
• Cash from Operations was 5481899.32 for Q1 2026 at Cardiol Therapeutics, down from 3746989.52 in the prior quarter.
• Across five years, Cash from Operations topped out at 1298440.3 in Q3 2022 and bottomed at 9242330.31 in Q4 2022.
• A 5-year average of 4722016.0 and a median of 4748595.89 in 2023 frame the typical range for Cash from Operations.
• Peak annual rise in Cash from Operations reached 74.4% in 2022, while the deepest fall reached 191.52% in 2022.
• Cardiol Therapeutics' Cash from Operations stood at 9242330.31 in 2022, then surged by 48.62% to 4748595.89 in 2023, then rose by 15.68% to 4003953.99 in 2024, then rose by 6.42% to 3746989.52 in 2025, then plunged by 46.3% to 5481899.32 in 2026.
• Business Quant data shows CRDL's Cash from Operations at 5481899.32 in Q1 2026, 3746989.52 in Q4 2025, and 5031955.39 in Q3 2025.